drugset / Trial / NCT06052787

Combined Cerebrolysin and Amantadine Sulfate Administration for Patients With Traumatic Brain Injury in the ICU

NCT06052787

Phase 3 Completed 150 enrolled Ain Shams University
RandomizedParallel-groupQuadruple-blindSupportive care

Summary

The goal of this interventional study is to Measure the potential benefits of combined administration of cerebrolysin and amantadine sulfate as an add-on therapy to the standard management of patients admitted to the ICU with traumatic brain injury.

Timeline

Start
2023-09-01
Primary completion
2025-05-30
Completion
2025-08-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Amantadine Unknown 200 mg
Subject Cerebrolysin Peptide 20 ml Intravenous